All posts by

26Jun/17

Neovii: Long-term Outcomes After Standard Graft-Versus-Host Disease (GvHD) Prophylaxis in Hemopoietic Cell Transplantation From Matched Unrelated Donors Strongly Support the Use of Grafalon® (Anti-Human-T-Lymphocyte Immunoglobulin) as Standard Therapy – PR Newswire

Neovii: Long-term Outcomes After Standard Graft-Versus-Host Disease (GvHD) Prophylaxis in Hemopoietic Cell Transplantation From Matched Unrelated Donors Strongly Support the Use of Grafalon® (Anti-Human-T-Lymphocyte Immunoglobulin) as Standard Therapy  PR Newswire

RAPPERSWIL, Switzerland, June 26, 2017 /PRNewswire/ — The 8-year follow-up results of a randomized phase 3 multicenter trial in adult patients with…